The name of the article I chose was “Brexanolone for the treatment of patients with postpartum depression”. It was published in final edit form in Drugs Today, 2019, and was written by K.E Morrison et al. This article is centered around the efficacy of the recently approved drug Zulresso also known as brexanolone. This drug in 2019, was the first drug approved specifically for the treatment of post-partum depression. This article discusses different trials to support the efficacy of this drug in the post-partum population. They did three double blind, randomized, placebo-controlled trials to observe the metabolism, safety, possibility of abuse, and concentrations in breast milk. article also outlines other aspects of the drug including its mechanism of action, adverse effects, and limitations. The article concluded that brexanolone appears to be safe and have a low side effect profile for both post-partum patients and their children if they are breast feeding. However, the article does admit that because the drug is new more studies need to be conducted to determine the possible long term effects the drug may have on both the mother and baby. I decided to pick this article for my site evaluation because I saw a couple postpartum patients during my rotation and wanted to know which treatment options are considered safe for them and their baby if they are indeed breastfeeding. During my research I found that in 2019 a drug had been FDA approved specifically for postpartum depression therefore I wanted to center my article presentation around this medication.